Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02863354 · ClinicalTrials.gov registry record · Phase 2
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
A Phase 2 study of Proliferative Diabetic Retinopathy, sponsored by Charles C Wykoff, PhD, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 4
- Study locations
NCT02863354 is a Phase 2 study of Proliferative Diabetic Retinopathy that has completed, run by Charles C Wykoff, PhD, MD. The registered enrollment target is 43 participants, below the 208-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT02863354, a Phase 2 study of Proliferative Diabetic Retinopathy, has completed, sponsored by Charles C Wykoff, PhD, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 4
- Study locations
Study Summary
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated with proliferative diabetic retinopathy (PDR). * Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 * Change in area of retinal capillary non-perfusion, as assessed by central reading center, from baseline through week 52
Conditions Studied
Interventions
- DRUG Aflibercept
Study Locations (4)
Texas
- Retina Consultants of Houston/The Medical Center - Houston
- Retina Consultants of Houston/Katy office - Katy
- Retina Consultants of Houston - Kingwood
- Retina Consultants of Houston - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02863354
The ClinicalTrials.gov registry entry for NCT02863354 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (79% lower). The listed sponsor is Charles C Wykoff, PhD, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Aflibercept is the first listed.
NCT02863354 reports 4 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02863354 about?
NCT02863354 is a clinical study titled "Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy". The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated with proliferative diabetic retinopathy (PDR). * Assess the safety and to...
What is the current status of trial NCT02863354?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-08. Estimated completion is 2019-05.
What conditions does trial NCT02863354 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT02863354?
The interventions under investigation include: Aflibercept (DRUG).
Who is sponsoring clinical trial NCT02863354?
This trial is sponsored by Charles C Wykoff, PhD, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02863354 being conducted?
This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
COMPLETED · Phase 2
-
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
COMPLETED · Phase 3
-
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.